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Abstract
 Anecdotal evidence supports the use of Bacrobial® skin cleanser for preventing muscle cramps; however, 
empirical evidence is lacking. OBJECTIVE: To examine whether Bacrobial® prevents muscle cramping in 
the triceps surae. DESIGN: Randomized, double-blind, placebo-controlled, crossover study. SETTINGS/
LOCATION: Laboratory. SUBJECTS: Seventeen cramp-prone participants (11 male, 6 female; age 21 ± 2 
yrs; 79.72 ± 19.75 kg; 175.86 ± 11.76 cm) volunteered. INTERVENTION: Participants completed two 
trials, at least one week apart. On the first trial, Bacrobial® was liberally applied to the skin over the triceps 
surae musculature of one leg, while placebo was applied to the other leg. At 1, 5, 10, and 20 min after 
application, participants were instructed to induce a cramp in the triceps surae via maximal voluntary 
contraction. For the second trial, treatments were applied to the opposite leg as in trial one and the 
cramping procedure was repeated. OUTCOME MEASURES: Incidence of cramping was the main 
outcome measure and event-odds tables, risk reduction and NNT (numbers needed to treat) or NNH 
(numbers needed to harm) were calculated at the time intervals of 1, 5, 10 and 20 minutes. RESULTS: No 
significant differences between treatments were found in cramping incidences at all time intervals. 
Bacrobial® decreased the risk of cramping by 12.5% at one minute (NNT = 8), while causing a 5.3% 
increased risk at five minutes (NNH = 5.3). CONCLUSIONS: Our findings indicate Bacrobial® skin 
cleanser is not an overall effective treatment for muscle cramp prevention. However, the observed results 
at one minute may be useful to clinicians who treat cramp-prone patients.
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1. Introduction
Muscle cramping is a common condition seen by 
health care professionals, and EAMC (exercise-
associated muscle cramping) is commonly treated by 
sports medicine professionals [1]. However, despite 
extensive research, the etiology of muscle cramping 
and best practice for treatment remains unknown. 
Several therapies have been used to prevent and treat 
muscle cramping, yet research on the efficacy of these 
therapies remains inconsistent [2]. 
Recently, growing anecdotal evidence has emerged 
for the use of a topical skin cleanser called Bacrobial
® 
(iFan Health Products, Inc., Black Mountain, NC) as an 
alternative therapy for preventing and treating muscle 
cramps,  especially  EAMC.  However,  no  empirical 
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studies have been published on the efficacy of this 
product. Therefore, the purpose of this study was to 
empirically examine the effect Bacrobial
® 
has on the
prevention of cramping in the triceps surae 
musculature. 
2. Materials and Methods
Seventeen participants (11 male, 6 female; age 21 ± 
2 yrs; 79.72 ± 19.75 kg; 175.86 ± 11.76 cm) 
volunteered for this IRB approved study. All 
participants completed a demographic and cramping 
history questionnaire and provided written informed 
consent prior to participation. 
A randomized, double-blind, placebo-controlled, 
crossover design was utilized. Unmarked 8oz spray 
bottles were filled with Bacrobial
® 
or placebo (purified
water with Bacrobial
® 
fragrance). Bacrobial
® 
topical
solution contains purified water, aloe, citrus based 
preservatives, tego betaine, allantoin, colloidal silver, 
 
lauryl glucoside, beta glucan, abil B, methylparaben 
propylparaben, EDTA (ethylenediaminetetraacetic 
acid), fragrance and vitamin E (US patent 6,358,516). 
A person unaffiliated with the study filled and marked 
the bottles with “A” and “B.” Identification was kept in 
a sealed envelope and not opened until the study was 
completed. 
A voluntary maximum contraction cramping 
protocol [3] was utilized to induce muscle cramping. 
Participants reported for three separate visits: a cramp 
induction screening visit and two intervention trial 
visits. Each visit was completed one week apart. 
2.1 Cramping Intervention Procedure: Trial One 
 
All participants were asked to report hydrated. 
Hydration status was verified by measuring urine 
specific gravity with a handheld refractometer (Model 
URC-Ne; ATAGO, USA; Bellevue, WA); if urine 
specific gravity was > 1.020, participants were required 
to reschedule on a different day. Participants were 
randomized to begin with either bottle-A or bottle-B on 
the right leg. The skin overlying the participant’s right 
triceps surae was liberally sprayed (~15 sprays) and 
lightly rubbed in by a researcher wearing non-latex 
gloves for approximately five seconds. After one 
minute, the participant performed the cramping 
protocol. If a cramp occurred within the 60-second 
time frame, the incidence (yes) was recorded and the 
cramp was relieved via stretching. If a cramp did not 
occur within 60 seconds, the attempt was stopped and 
incidence (no) was recorded. The protocol was 
repeated at 5, 10 and 20 minutes from application. 
After completion on the right leg, the opposite spray 
and cramping procedure was performed on the left leg. 
2.2 Cramping Intervention Procedure: Trial Two 
 
Participants returned one week later and the same 
protocol from trial one was repeated. However, the 
solutions were crossed over (i.e., if the participant had 
bottle-A sprayed on the right leg in trial one, bottle-B 
was sprayed on the right leg in trial two). 
2.3 Statistical Analyses 
 
Event-odds tables were calculated based on the 
outcome variable of cramping across Bacrobial
® 
and 
placebo groups at time intervals of 1, 5, 10, and 20 
minutes from initial application. Our data did not meet 
assumptions for chi-squared analysis (expected values 
< 5). Therefore, differences between groups were 
calculated using a two-way Fisher’s exact test. An a 
priori level of significance was set a 0.05. Additionally, 
risk reduction and NNT (numbers needed to treat) or 
NNH (numbers needed to harm) were also calculated 
from event odds tables. 
3. Results 
Cramping incidences are displayed in Table 1. No 
significant differences were observed in cramping 
incidence between Bacrobial
® 
and placebo groups at 1 
minute (P = 0.484), 5 minutes (P = 0.333), 10 minutes 
(P = 1.000), or 20 minutes (P = 1.000). Bacrobial
® 
decreased the risk of cramping by 12.5% at 1 minute 
(NNT = 8); while causing a 5.3% increased risk at 5 
minutes (NNH = 5.3). At 10 and 20 minutes, there 
were no changes in risk reduction between groups. 
4. Discussion 
Despite  an  abundance  of  anecdotal   evidence, 
our findings suggest that Bacrobial
® 
is not an overall 
 
Table 1   Cramping incidences and Fisher exact significance. 
 
Group Cramp? 1 min 5 min 10 min 20 min 
Treatment 
Yes 14 15 14 14 
 No 2 1 2 2 
Placebo 
Yes 16 12 14 14 
 No 0 4 2 2 
Fisher exact significance  0.484 0.333 1.000 1.000 
 
 
effective alternative treatment for preventing muscle 
cramps. The most clinically significant finding of this 
study was that Bacrobial® made participants 12.5% 
less likely to cramp one minute post-application. This 
information could be useful to clinicians working with 
cramp-prone individuals. 
Many different therapies have been studied for the 
prevention and treatment of muscle cramps. Hydration 
and electrolyte replacement have long been promoted 
to reduce EAMC, yet little evidence supports these 
interventions [1]. Results remain mixed on the use of 
stretching [1] and ingestion of pickle juice [4] as a 
prevention therapy. One well-studied pharmacological 
treatment that is highly effective in reducing muscle 
cramps is quinine sulfate [5]; however, the side effects 
associated with quinine sulfate ingestion suggest 
caution of its use as a long-term treatment. Calcium 
channel blockers, Verapamil [6] and Diltiazem [7], 
have proven effective in treating nocturnal muscle 
cramps, but with many pharmaceuticals there are risks 
of adverse side effects. 
Non-prescription treatment of muscle cramps has 
shown promise. In a small study, ingestion of vitamin 
B complex reduced the frequency, duration and 
intensity of cramps [8]. Vitamin E has also been used to 
successfully alleviate muscle cramps in hemodialysis 
patients, but not for nocturnal muscle cramps [9, 10]; 
however, the mechanism by which vitamin E functions 
to relieve muscle cramps is unknown. The limited 
effectiveness of Bacrobial® may be explained by the 
presence of EDTA. This chemical possesses calcium-
chelating properties and may function to sequester 
calcium ions in the muscle fiber after rapid 
transdermal absorption. This may also help explain 
why we observed a reduced risk of cramping at one 
minute post-application, but an increased risk at five 
minutes. 
5. Conclusions 
Although Bacrobial
® 
skin cleanser does not appear, 
overall, to be an effective treatment for the prevention 
 
 
of muscle cramps, the observed results at one minute 
may be useful to clinicians who frequently treat 
patients who are prone to cramping. It is unknown 
whether Bacrobial
® 
works to treat (relieve) muscle 
cramps once a cramp has occurred, thus future research 
should investigate whether Bacrobial
® 
is effective to 
treat muscle cramps, as well as whether re-application 
works to reduce subsequent cramping. 
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